Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions
Executive Summary
Ongoing discussions about a risk management plan for Genentech's Raptiva (efalizumab) may provide an avenue to maintain the psoriasis drug's commercial viability, despite its safety problems